Licensing Deal and UK Launch

Advanced Medical Solutions Grp PLC
16 December 2004


For Immediate Release                                                                                      16 December 
2004




         Advanced Medical Solutions Group plc ('AMS' or 'the Company')

       Licensing deal and UK launch of new skin closure system SkinLinkTM


Winsford, UK: Advanced Medical Solutions (AIM: AMS), the global wound care
technology company, today announces that it has licensed a novel wound closure
product, SkinLinkTM, from the Canadian company Biogentis and also entered into a
manufacturing agreement. The SkinLinkTM product, which will be launched
immediately in the UK, consists of a perforated adhesive strip, on which an
anchoring topical adhesive is applied.

The SkinLinkTM product offers significant benefits over current products such
as sutures, staples or conventional adhesive strips in closing topical wounds
where medical glues are inappropriate, such as where there is significant
swelling or tissue loss. The product will be added to the range of wound closure
products offered by AMS's MedLogic division. MedLogic is the UK's market leader
in the use of medical glues for closing topical wounds in the Accident and
Emergency (A&E) arena and the addition of SkinLinkTM to the MedLogic range will
allow a much broader range of indications to be covered.

Under the terms of the licensing agreement, MedLogic will have exclusive
distribution rights in the UK for the SkinLinkTM product and a manufacturing
licence to supply the product to Biogentis for other markets.  The SkinLinkTM
product will consist of Biogentis' adhesive strip technology coupled with
MedLogic's cyanoacrylate topical glue for sale as a skin closure system into
both A&E departments and operating theatres.  The product received a positive
response when shown at a recent UK woundcare conference and  goes on general
sale in the UK with immediate effect.

Montreal-based Biogentis is a technology company with activities covering the
development and commercialisation of skin closure systems, research and
development and phase II clinical trial activities for chronic wound healing
(venous ulcers) therapies and the development of a human tissue-based range of
biologic products for therapeutics applications.


Commenting on this announcement, Dr. Don Evans, Chief Executive of AMS, stated:


'I am delighted that we have been able to obtain manufacturing and UK
distribution rights to this innovative skin closure system from Biogentis.  It
broadens our product portfolio, allowing us to cover the vast majority of
indications for wound closure in A&E and operating theatres in the UK with
simple, non-invasive products, which minimise patient trauma whilst providing
good clinical and cosmetic outcomes.'


Jean-Pierre Robert, President and Chief Executive of Biogentis, added:

'The completion of this licensing deal with AMS's MedLogic division, a leading
company in the highly competitive UK wound closure market, provides strong
validation of our SkinLinkTM technology.  By utilising their experience in
cyanoacrylate topical glues and manufacturing capabilities, we look forward to
success in the UK and in growing the business in other markets.'



For further information, please contact:

Advanced Medical Solutions Group plc                                            Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                                                         Tel: [phone]
Mark Court, Mary-Jane Johnson



Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to hospitals or
through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Smith + Nephew and  Cardinal Health.


                      This information is provided by RNS
            The company news service from the London Stock Exchange